These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26779459)

  • 1. Nonvisible tumors on multiparametric magnetic resonance imaging does not predict low-risk prostate cancer.
    Lee SH; Koo KC; Lee DH; Chung BH
    Prostate Int; 2015 Dec; 3(4):127-31. PubMed ID: 26779459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.
    Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
    Jpn J Clin Oncol; 2013 May; 43(5):553-8. PubMed ID: 23580758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.
    Somford DM; Hamoen EH; Fütterer JJ; van Basten JP; Hulsbergen-van de Kaa CA; Vreuls W; van Oort IM; Vergunst H; Kiemeney LA; Barentsz JO; Witjes JA
    J Urol; 2013 Nov; 190(5):1728-34. PubMed ID: 23680307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance.
    Park BH; Jeon HG; Choo SH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
    BJU Int; 2014 Jun; 113(6):864-70. PubMed ID: 24053308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance.
    Tran GN; Leapman MS; Nguyen HG; Cowan JE; Shinohara K; Westphalen AC; Carroll PR
    Eur Urol; 2017 Aug; 72(2):275-281. PubMed ID: 27595378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
    Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
    Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of unfavorable disease after radical prostatectomy in patients at low risk by D'Amico criteria: role of multiparametric magnetic resonance imaging.
    Song SH; Pak S; Park S; Song C; Jeong IG; Choi HJ; Kim JK; Cho KS; Kim CS; Ahn H
    J Urol; 2014 Aug; 192(2):402-8. PubMed ID: 24631106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer: role of pretreatment multiparametric 3-T MRI in predicting biochemical recurrence after radical prostatectomy.
    Park JJ; Kim CK; Park SY; Park BK; Lee HM; Cho SW
    AJR Am J Roentgenol; 2014 May; 202(5):W459-65. PubMed ID: 24758681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation?
    Cornud F; Khoury G; Bouazza N; Beuvon F; Peyromaure M; Flam T; Zerbib M; Legmann P; Delongchamps NB
    J Urol; 2014 May; 191(5):1272-9. PubMed ID: 24333516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of ADC, T2 signal intensity, and a combination of both parameters to assess Gleason score and primary Gleason grades in patients with known prostate cancer.
    Nowak J; Malzahn U; Baur AD; Reichelt U; Franiel T; Hamm B; Durmus T
    Acta Radiol; 2016 Jan; 57(1):107-14. PubMed ID: 25505225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct comparison of multiparametric magnetic resonance imaging (MRI) results with final histopathology in patients with proven prostate cancer in MRI/ultrasonography-fusion biopsy.
    Borkowetz A; Platzek I; Toma M; Renner T; Herout R; Baunacke M; Laniado M; Baretton G; Froehner M; Zastrow S; Wirth M
    BJU Int; 2016 Aug; 118(2):213-20. PubMed ID: 26935133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADC Metrics From Multiparametric MRI: Histologic Downgrading of Gleason Score 9 or 10 Prostate Cancers Diagnosed at Nontargeted Transrectal Ultrasound-Guided Biopsy.
    Sadoughi N; Krishna S; McInnes MDF; Flood TA; Breau RH; Morash C; Schieda N
    AJR Am J Roentgenol; 2018 Sep; 211(3):W158-W165. PubMed ID: 29995495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-Tumor Quantitative Apparent Diffusion Coefficient Histogram and Texture Analysis to Predict Gleason Score Upgrading in Intermediate-Risk 3 + 4 = 7 Prostate Cancer.
    Rozenberg R; Thornhill RE; Flood TA; Hakim SW; Lim C; Schieda N
    AJR Am J Roentgenol; 2016 Apr; 206(4):775-82. PubMed ID: 27003049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer.
    Kamrava M; Kishan AU; Margolis DJ; Huang J; Dorey F; Lieu P; Kupelian PA; Marks LS
    Pract Radiat Oncol; 2015; 5(6):411-6. PubMed ID: 26059510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
    Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
    AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates.
    Altok M; Troncoso P; Achim MF; Matin SF; Gonzalez GN; Davis JW
    Asian J Androl; 2019; 21(6):598-604. PubMed ID: 31115364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward Prostate Cancer Contouring Guidelines on Magnetic Resonance Imaging: Dominant Lesion Gross and Clinical Target Volume Coverage Via Accurate Histology Fusion.
    Gibson E; Bauman GS; Romagnoli C; Cool DW; Bastian-Jordan M; Kassam Z; Gaed M; Moussa M; Gómez JA; Pautler SE; Chin JL; Crukley C; Haider MA; Fenster A; Ward AD
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):188-96. PubMed ID: 27375167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
    Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
    Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of Multiparametric MRI of Prostate in Patients under Consideration for or Already in Active Surveillance: Correlation with Imaging Guided Target Biopsy.
    Yu J; Fulcher AS; Winks S; Turner MA; Behl W; Ware AL; Mukhopadhyay ND; Kim C; Jackson C; Bajaj HS; Hampton LJ
    Diagnostics (Basel); 2020 Jun; 10(7):. PubMed ID: 32610595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.